A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: bimekizumab
DRUG: ustekinumab
DRUG: placebo

Sponsor

UCB Biopharma SRL